TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9833950
Drug: Oral N-acetyl-L-cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral N-acetyl-L-cysteine (1,200 mg/day)
Study: 2518872
Drug: Antacid (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (one tablet q.d.s. for 1.5 days)
Study: 2518872
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one tablet q.d.s. for 1.5 days)
Study: 1053551
Drug: Sublingual isosorbide
Normalized name: isosorbide dinitrate Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual isosorbide dinitrate (SISD)
Study: 29960290
Drug: Lianhuaqingwen capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lianhuaqingwen capsules
Study: 16894335
Drug: ERr 731
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ERr 731 (one enteric-coated tablet daily for 12 weeks)
Study: 8190435
Drug: Oxytocin augmentation
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin augmentation with intact chorioamnion
Study: 8190435
Drug: Oxytocin augmentation
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin augmentation with amniotomy and internal monitoring
Study: 18931095
Drug: Liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8 mg/day
Study: 28094194
Drug: MABp1 (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MABp1 (7.5 mg/kg every 2 weeks for 8 weeks)
Study: 19853417
Drug: Medication and
Normalized name: CVS Health Medication and Topical Refill Pouch KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication and Placebo
Study: 16903245
Drug: Postpartum treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postpartum treatment (three months after delivery)
Study: 11884000
Drug: Oral multivitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral multivitamins from the first day of admission
Study: 2955324
Drug: Indomethacin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 0.1 mg/kg
Study: 14602694
Drug: Indomethacin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 0.2 mg/kg
Study: 26460504
Drug: Darunavir/ritonavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir monotherapy (DRV/r) 800/100 mg once daily for 48 weeks
Study: 22739371
Drug: Cholecalciferol 15
Normalized name: Cholecalciferol 150 MCG/1 DRP Oral Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 15 μg/d (D3-15)
Study: 22739371
Drug: Cholecalciferol 10
Normalized name: cholecalciferol 100 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 10 μg/d (D3-10)
Study: 22739371
Drug: Cholecalciferol 5
Normalized name: cholecalciferol 50 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 5 μg/d (D3-5)
Study: 22739371
Drug: Cholecalciferol 0
Normalized name: cholecalciferol 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 0 μg/d (P)
Study: 22739371
Drug: Cholecalciferol (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (any dose)
Study: 18479176
Drug: Lornoxicam quick-release
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam quick-release tablet (QR)
Study: 18479176
Drug: Lornoxicam standard
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam standard tablet (ST)
Study: 18479176
Drug: Lornoxicam intramuscular
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam intramuscular injection (IM)
Study: 16140282
Drug: Olanzapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (mean 11.30 mg/day)
Study: 16140282
Drug: Haloperidol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (mean 4.87 mg/day)
Study: 1422754
Drug: Lomoparan (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomoparan (750 anti-Xa units subcutaneously twice a day)
Study: 1422754
Drug: Heparin-DHE 5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-DHE 5000 (5000 units heparin and 0.5 mg dihydroergotamine subcutaneously twice a day)
Study: 1422754
Drug: Heparin-DHE 5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-DHE 5000
Study: 6708033
Drug: Placebo (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5% dextrose in lactated Ringer's solution)
Study: 12955901
Drug: Conventional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medication
Study: 29975203
Drug: Preoperative fascia
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative fascia iliaca block with 40 ml ropivacaine 0.2%
Study: 16123896
Drug: Hymecromone 800
Normalized name: hymecromone
DrugBank: Hymecromone (DB07118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hymecromone 800 mg p.o. with standardized meal (Biloptin, 40 gs)
Study: 12893113
Drug: Various antiepileptic
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various antiepileptic drugs used to treat seizure disorder
Study: 12893113
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of intractable epilepsy
Study: 1995721
Drug: Rhesus rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus rotavirus vaccine (10^4 pfu)
Study: 1995721
Drug: RIT 4237
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, RIT-4385 strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIT 4237 vaccine (10^8 pfu)
Study: 22575075
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg pregabalin
Study: 30115911
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg pregabalin
Study: 22575075
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg pregabalin
Study: 22575075
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg pregabalin
Study: 17436845
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy using a sensory integration approach (OT‐SI)
Study: 15821119
Drug: Analgesic Protocol
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic Protocol (AP)
Study: 7836622
Drug: Three different
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three different magnesium oxide preparations
Study: 2873966
Drug: Endralazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endralazine (10 mg to 30 mg per day)
Study: 2873966
Drug: Hydralazine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (75 mg to 200 mg per day)
Study: 16931259
Drug: Trypan blue
Normalized name: Trypan Blue
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trypan blue 0.0125% solution (Group 1, n = 20)
Study: 16931259
Drug: No anterior
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anterior capsule staining (Group 2, n = 20)
Study: 10479911
Drug: Chemotherapy (ChT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (ChT)
Study: 22916226
Drug: Closantel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closantel treatment at dry-off
Study: 19147504
Drug: HSA+serum substitute
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSA+serum substitute supplement (SSS)
Study: 19147504
Drug: HSA (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSA (as the sole protein supplement)
Study: 17971178
Drug: Low-carbohydrate diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate diet (<= 40 g carbohydrate/day)
Study: 15609594
Drug: Xuefu Zhuyu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuefu Zhuyu decoction (XZD) with conventional liver protective treatment
Study: 15609594
Drug: Conventional liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional liver protective treatment alone
Study: 8895147
Drug: DP-1904 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP-1904 (400 mg/day bid)
Study: 8895147
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg/day bid)
Study: 1806334
Drug: beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beclomethasone dipropionate 300 mcg/day
Study: 6354522
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MCP) infusion during low sodium intake (10 mmol)
Study: 6354522
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MCP) infusion during high sodium intake (200 mmol)
Study: 30610213
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg curcumin
Study: 26134371
Drug: Doxycycline therapy
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline therapy
Study: 21725634
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg flurbiprofen axetil preoperative, 10 μg/kg fentanyl + 100 mg flurbiprofen axetil postoperative (Group B)
Study: 21725634
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg flurbiprofen axetil preoperative, 10 μg/kg fentanyl + 10 ml placebo postoperative (Group A)
Study: 21725634
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml placebo preoperative, 10 μg/kg fentanyl + 10 ml placebo postoperative (Group C)
Study: 18445098
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori screening and treatment
Study: 16902311
Drug: Weekly or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly or more frequent monitoring
Study: 12499335
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of supplement (200 mg vitamin E, 300 mg vitamin C, 25 mg beta-carotene, 90 micro g Se, and 500 micro g vitamin A)
Study: 12499335
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of supplement (10 mg vitamin E and 500 micro g vitamin A)
Study: 12499335
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of supplement
Study: 2003341
Drug: Trimethoprim and
Normalized name: Trimethoprim and derivatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim and sulfamethoxazole (TMP/SMX) taken orally twice a day for seven days
Study: 6663617
Drug: Lens-implant or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lens-implant or contact-lens correction
Study: 28942334
Drug: 25-μg rhPTH(1‐84)
Normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25-μg rhPTH(1‐84) daily dose
Study: 28942334
Drug: 50-μg rhPTH(1‐84)
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-μg rhPTH(1‐84) daily dose
Study: 17468682
Drug: Efficacious treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efficacious treatment
Study: 11305822
Drug: Flurbiprofen 1
Normalized name: flurbiprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 1 mg x kg(‐1) iv 30 min before surgery (PRE)
Study: 11305822
Drug: Flurbiprofen 1
Normalized name: flurbiprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 1 mg x kg(‐1) iv at the end of surgery (POST)
Study: 3598225
Drug: 100% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% of the standard im dose of HDCV
Study: 3598225
Drug: 10% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% of the standard im dose of HDCV
Study: 3598225
Drug: 3% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% of the standard im dose of HDCV
Study: 3598225
Drug: 10% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% of the standard im dose id of HDCV
Study: 3598225
Drug: 3% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% of the standard im dose id of HDCV
Study: 23818758
Drug: Higher-dose inhaled
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose inhaled corticosteroids (ICS) in combination with long-acting beta-agonist (LABA) for one month, then shifted to guideline doses.
Study: 23818758
Drug: Guideline doses
Normalized name: LARYNGEAL GUIDEWIRE,PROVOX #7215
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline doses (GD) therapy alone.
Study: 20524439
Drug: Ketotifen (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (0.5 mg or 1 mg orally twice daily)
Study: 20524439
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 microg inhaled twice daily)
Study: 16600723
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg daily for 24 months
Study: 12677572
Drug: TMP/SMZ (TMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP/SMZ (TMP 4 mg/kg/d and SMZ 20 mg/kg/d, divided in 2 doses)
Study: 12677572
Drug: Neomycin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin (25 mg/kg/d, qid, 4 days a week)
Study: 8373610
Drug: PGE1 (0.11
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE1 (0.11 +/- 0.03 micrograms/kg/min) infusion
Study: 27426276
Drug: Pramipexole (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (titrated from 0.09 to 0.54 mg, o.d., for 3 weeks)
Study: 17216435
Drug: Mefloquine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (250 mg base daily for 3 days, then 250 mg weekly for 6 months)
Study: 15161780
Drug: Multifaceted provider-level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted provider-level intervention (six monthly visits by a multidisciplinary health care team)
Study: 7997385
Drug: Torsemide 5
Normalized name: torsemide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torsemide 5 mg
Study: 7997385
Drug: Torsemide 10
Normalized name: torsemide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torsemide 10 mg
Study: 7997385
Drug: Torsemide 20
Normalized name: torsemide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torsemide 20 mg
Study: 30689618
Drug: Light-emitting diode
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light-emitting diode therapy (LEDT) applied to biceps brachii after strength training
Study: 25307829
Drug: Multidisciplinary group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary group-based rehabilitation program with monthly motivational consultation
Study: 25307829
Drug: Oral drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drug treatment alone
Study: 25715157
Drug: CPS5‐TT/CPS8‐TT/AT/ClfA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPS5‐TT/CPS8‐TT/AT/ClfA vaccine (5/5/10/10 μg or 10/10/30/30 μg dose with or without AS03B adjuvant)
Study: 21333346
Drug: High-dose maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose maintenance vaccine (4200 allergen units, approximately 70 μg of Der f 1/d)
Study: 21333346
Drug: Low-dose maintenance
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose maintenance vaccine (60 allergen units, approximately 1 μg of Der f 1/d)
Study: 14660478
Drug: Ribose (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribose (200 mg/kg body wt; Rib)
Study: 9822512
Drug: Clindamycin 900
Normalized name: clindamycin 900 MG in 6 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 900 mg every 8 hours and gentamicin 1.5 mg/kg every 8 hours until afebrile for a minimum of 24 hours (group 2)
Study: 9822512
Drug: No scheduled
Approvals — FDA: no, EMA: no, PMDA: no
Description: No scheduled postoperative antibiotics (group 1)
Study: 7853818
Drug: Gastrozepin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrozepin treatment
Study: 7853818
Drug: Ranisan treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranisan treatment
Study: 30841744
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy augmented with movement or occupational therapy (n=23)
Study: 28625506
Drug: lixisenatide 20
Normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: lixisenatide 20 μg
Study: 25792607
Drug: Mass isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mass isoniazid preventive therapy for 9 months
Study: 25792607
Drug: Additional interventions
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional interventions (improving diagnostics, reducing treatment delay, providing continuous isoniazid preventive therapy to HIV-positive people, scaling up antiretroviral treatment coverage)
Study: 18165596
Drug: IV patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV patient-controlled morphine
Study: 12590006
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate (10 mg/day, n=18)
Study: 11794823
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormone replacement therapy (0.625 mg conjugated estrogen/day combined with medroxyprogesterone 5 mg/day)
Study: 11794823
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormone replacement therapy plus pravastatin
Study: 8683230
Drug: Anastrozole 10
Normalized name: anastrozole 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 10 mg once daily
Study: 9740079
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 40 mg 4 times daily
Study: 2659442
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 3 g amoxicillin (group A)
Study: 2659442
Drug: 4-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day course of 3 X 750 mg amoxicillin (group B)
Study: 4613531
Drug: Prostaglandin F2alpha
Normalized name: Prostaglandin F2alpha tham
DrugBank: Dinoprost tromethamine (DB01160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin F2alpha (PGF2alpha) administered extraamniotically
Study: 4613531
Drug: Prostaglandin F2alpha
Normalized name: Prostaglandin F2alpha tham
DrugBank: Dinoprost tromethamine (DB01160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin F2alpha (PGF2alpha) administered intraamniotically
Study: 30464914
Drug: i/v ceftazidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i/v ceftazidine 1 gm bd with oral ciprofloxacin 750 mg bd
Study: 30464914
Drug: surgical debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: surgical debridement with oral ciprofloxacin 750 mg bd
Study: 26466613
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg od (or 15 mg od in patients with moderate renal insufficiency)
Study: 26466613
Drug: Warfarin (INR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (INR target 2.5)
Study: 17145785
Drug: Crushed voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crushed voriconazole tablets
Study: 17145785
Drug: Whole voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whole voriconazole tablets
Study: 11993619
Drug: Low rate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low rate of fluid intake (L) - 120% of BW loss ingested at 24% x h(‐1) during 5 hours.
Study: 7795155
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day beta‐carotene for 14 weeks
Study: 1693411
Drug: Amoxicillin combined
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin combined with xylometazoline hydrochloride nose drops
Study: 1693411
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of maxillary sinus drainage and amoxicillin with xylometazoline
Study: 28234636
Drug: Ropivacaine-based periarticular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine-based periarticular injection
Study: 28234636
Drug: Liposomal bupivacaine-based
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine-based periarticular injection
Study: 25275888
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg·kg(‐1))
Study: 15339328
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg/q.d.s.
Study: 15339328
Drug: Pantoprazole 20
Normalized name: pantoprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 20 mg/q.d.s.
Study: 15339328
Drug: Pantoprazole 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 10 mg/q.d.s.
Study: 15339328
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg/b.d.
Study: 1825037
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of acetylcholine or ergonovine
Study: 23192720
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (Control)
Study: 31775837
Drug: Bolus therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus therapy with 20-40 ml/kg 5% albumin or 0.9% saline over 1-2 h
Study: 31775837
Drug: No bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bolus (control, 4 ml/kg/hour maintenance)
Study: 8390287
Drug: Bolus therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus therapy